c1

Problem=Opportunity

✓ Reduced efficacy of actual vaccines

✓ Short duration of immunity

✓ No cross-protection against different strains

✓ Biosafety issues

✓ Imperfect costs for end users

Vaccination offers an effective,

inexpensive way to safeguarding the

health and welfare of animals, however

there is still room for innovations

2

VP2 protein is a structural protein of

the Infectious Bursitis virus (IBDV)

what naturally autoassemble

forming Virus-Like Particles

Translation

Assembling

process

x60

VLPs

VP2

protein

VP2 gene

Ch-VLP Platform: Technology Basis

3

Chimeric

VP2

proteins

Ch-VLP Platform: Technology Basis

Chimeric

VP2 gene

Displaying selected epitopes, we can

design chimeric virus like particles

to stimulate the most adequate

response against the target

pathology.

Translation

Chimeric

VLPs

4

Ch-VLP Platform: Technology Basis

5

0%

20%

40%

60%

80%

100%

0 10 20 30 40 50 60

Surv

ival

Rat

e (%

)

Time (Days)

Ch-VLP

Epitope

Control

• High Efficiency: Boosted and durable host immune response.

Ch-VLP Platform: Main Advantages

6

Antibodies titer

Ant-VP1 Ant-VP2 Ant-VP3

• Differentiating Infected from Vaccinated Animals (DIVA).

• High Efficiency: Boosted and durable host immune response.

Ch-VLP Platform: Main Advantages

7

• Biosafety: without genetic material it is not able to autoreplicate.

• Differentiating Infected from Vaccinated Animals (DIVA).

• High Efficiency: Boosted and durable host immune response.

Ch-VLP Platform: Main Advantages

8

• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying

different antigens (cellular, humoral or both), consensus sequences, multiple targets…

• Biosafety: without genetic material it is not able to autoreplicate.

• Differentiating Infected from Vaccinated Animals (DIVA).

• High Efficiency: Boosted and durable host immune response.

Ch-VLP Platform: Main Advantages

9

• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying

different antigens (cellular, humoral or both), consensus sequences, multiple targets…

• Biosafety: without genetic material it is not able to autoreplicate.

• Low-cost production system: Already validated in several hosts

• Differentiating Infected from Vaccinated Animals (DIVA).

• High Efficiency: Boosted and durable host immune response.

Ch-VLP Platform: Main Advantages

10

Product Development Roadmap

Preliminary Process

DevelopmentPreliminary

immunogenicity/efficacy

Regulatory Studies Registration

CommercializationIdeaFMD TeStop PRRSV IBDVBVDVPCV2

Prototypes generation

Our Ch-VLPs are ideal vehicles to generate vaccines

against animal pathologies in which protection is

dependent on one or few well-known epitopes

ASFV, Horse Flu, Pet

oncology, etc.

Potential New

Developments

VLPbio Products Portfolio

11

Our products portfolio already contents products against the main

impacting diseases in the veterinary field, targeting a global market

of >1 Billion of Euros.

New vaccines development against the most impacting diseases

- Well recognized and challenging diseases

- Globally distributed diseases

- Competitive landscape

VLPbio Target Market

12

Thank you

VLPbio is a technological company that provide a first-class technology for the development of

new vaccines with differentiating properties to be successfully applied in animal health

The company has a strong and diversified portfolio of products on development for the most

important diseases not properly covered.

To Conclude

13

c1

983 54 85 63

www.VLPbio.com

info@VLPbio.com

@VLPbio

VLPbio14